PBS Biotech, a leading developer of innovative single-use bioreactor technologies for cell therapy manufacturing, today announced it has been named Cell Therapy Products Development of the Year 2026 ...

SC451 for type 1 diabetes drives upside, but valuation & dilution risk loom. Click here to read more about the SANA stock.

CARLSBAD, Calif.-- (BUSINESS WIRE)--Jul 30, 2026-- ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today ...

Panel A shows positron-emission tomographic images obtained with the use of the glucagon-like peptide-1 receptor (GLP-1R)–targeting radiotracer [68 Ga]Ga-NODAGA-exendin-4 at 12 months after ...

Industry leaders share solutions for overcoming cell and gene therapy bioprocessing-manufacturing challenges and scalability barriers.

Learn how effective technology transfer helps cell therapy developers navigate GMP manufacturing, regulatory requirements and ...

Over the past several decades, the semiconductor industry has experienced sustained growth. Early expansion was driven by the widespread adoption of personal computers, while today demand is fueled by ...

Nova aims to quicken cell line development and create a stronger foundation for downstream process development, scaleup, and ...

CASGEVY is a non-viral, ex vivo, CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT that has been ...

Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes ...